PITTSBURGH, Jan. 14 — A gene from the measles virus plays a key role in the development of Paget’s disease of bone, according to a team of researchers led by the University of Pittsburgh School of Medicine. Their findings, recently published in Cell Metabolism, confirm a long-held speculation that the childhood infection is an environmental trigger for the disease and reveal how the viral gene contributes to the development of its characteristic bone lesions.
“Our earlier work showed that bone cells called osteoclasts in about 70 percent of these patients contain a certain measles virus protein,” noted senior investigator, G. David Roodman, M.D., Ph.D., professor and vice chair for research, Department of Medicine. “Also, when we engineered normal osteoclasts in mice to contain, or express, the measles protein, pagetic bone lesions formed.”
Osteoclast abnormalities lead to imbalance in the normal processes of bone dissolution and rebuilding. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, an estimated 1 million Americans have Paget’s disease (PD) of bone. Bones are enlarged but fragile, leading to pain and a greater likelihood of fracture. Arthritis, hearing loss and kidney stones can occur.
In the new study, Dr. Roodman’s team sought to understand the roles of mutations in a gene called p62, which is common among PD patients, and measles virus nucleocapsid protein (MVNP) by examining the marrow of affected and unaffected bones of 12 PD patients and of eight people without PD. They also bred mice with the p62 mutation and MVNP.
The team found that marrow from eight of the 12 PD patients expressed MVNP; three patients expressed the protein in both affected and unaffected bone sites, and four patients did not make it at either type of site. Osteoclast precursor cells from PD patients who made MVNP formed pagetic osteoclasts in test tube experiments and displayed other typical PD responses. Osteoclasts appeared normal, though, when the precursor cells came from PD patients who didn’t make MVNP.
“It’s not clear why this would happen,” Dr. Roodman said. “It could be that other viruses or genes are triggering PD in these patients.”
Mice with a p62 gene mutation and MVNP developed dramatic bone lesions. Other tests indicate that the presence of MVNP increases production of the cell-signaling protein interleukin-6, which in turn leads to osteoclast changes that are seen in PD.
The prevalence of Paget’s disease has dropped during the past 25 years, Dr. Roodman said. That could reflect the impact of measles vaccination or that another environmental factor involved in PD has changed.
Co-authors include lead author Noriyoshi Kurihara, D.D.S., Ph.D., and others from the University of Pittsburgh School of Medicine, as well as researchers from Teijin Bio-Medical Research, Tokyo, Japan; Laval University, Quebec City, Que.; Helen Hayes Hospital, West Haverstraw, N.Y.; Columbia University, New York; and Virginia Commonwealth University, Richmond, Va.
The study was funded by the National Institutes of Health and the Paget’s Foundation.
About the University of Pittsburgh School of Medicine
As one of the nation’s leading academic centers for biomedical research, the University of Pittsburgh School of Medicine integrates advanced technology with basic science across a broad range of disciplines in a continuous quest to harness the power of new knowledge and improve the human condition. Driven mainly by the School of Medicine and its affiliates, Pitt has ranked among the top 10 recipients of funding from the National Institutes of Health since 1997 and now ranks fifth in the nation, according to NIH data for 2008 (the most recent year for which the data are final).
Likewise, the School of Medicine is equally committed to advancing the quality and strength of its medical and graduate education programs, for which it is recognized as an innovative leader, and to training highly skilled, compassionate clinicians and creative scientists well-equipped to engage in world-class research. The School of Medicine is the academic partner of UPMC, which has collaborated with the University to raise the standard of medical excellence in Pittsburgh and to position health care as a driving force behind the region’s economy. For more information about the School of Medicine, see www.medschool.pitt.edu.
